Myl-1401O regulatory update

Mylan and Biocon said Mylan submitted a BLA to FDA for Myl-1401O, a biosimilar of Herceptin trastuzumab, to treat HER2-positive breast and gastric cancers. In August, EMA accepted for review an MAA fo...